Log in
Enquire now
‌

US Patent 9944709 CD123 specific chimeric antigen receptors for cancer immunotherapy

Patent 9944709 was granted and assigned to Cellectis on April, 2018 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Cellectis
Cellectis
Current Assignee
Cellectis
Cellectis
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
9944709
Date of Patent
April 17, 2018
Patent Application Number
15126540
Date Filed
March 19, 2015
Patent Citations Received
‌
US Patent 11919961 CD123 specific chimeric antigen receptors for cancer immunotherapy
0
‌
US Patent 11692039 Multifunctional natural killer (NK) cell engagers binding to NKp46 and CD123
0
‌
US Patent 11708572 Acoustic cell separation techniques and processes
0
Patent Primary Examiner
‌
Jessica H Roark
Patent abstract

The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a CD123 monoclonal antibody, conferring specific immunity against CD123 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9944709 CD123 specific chimeric antigen receptors for cancer immunotherapy

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us